• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    1/19/24 12:31:10 PM ET
    $ADAG
    $ALVO
    $AXDX
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ADAG alert in real time by email

    Gainers

    • Edgewise Therapeutics (NASDAQ:EWTX) stock moved upwards by 35.8% to $13.15 during Friday's regular session. The market value of their outstanding shares is at $834.8 million.
    • Bullfrog AI Hldgs (NASDAQ:BFRG) shares moved upwards by 32.13% to $5.14. The company's market cap stands at $31.3 million.
    • Shuttle Pharmaceuticals (NASDAQ:SHPH) shares moved upwards by 23.51% to $0.55. The company's market cap stands at $8.7 million.
    • NightHawk Biosciences (AMEX:NHWK) shares increased by 16.58% to $0.42. The market value of their outstanding shares is at $10.9 million.
    • Alvotech (NASDAQ:ALVO) shares rose 14.3% to $14.02. The market value of their outstanding shares is at $3.7 billion.
    • Tenaya Therapeutics (NASDAQ:TNYA) shares increased by 11.73% to $3.56. The market value of their outstanding shares is at $242.7 million.

    Losers

    • Accelerate Diagnostics (NASDAQ:AXDX) stock declined by 34.0% to $1.06 during Friday's regular session. The company's market cap stands at $15.4 million.
    • Anitra (AMEX:AZTR) shares fell 31.71% to $1.4. The market value of their outstanding shares is at $16.9 million.
    • TransCode Therapeutics (NASDAQ:RNAZ) shares fell 28.49% to $0.78.
    • BioCardia (NASDAQ:BCDA) shares declined by 23.94% to $0.44. The company's market cap stands at $10.3 million.
    • Adagene (NASDAQ:ADAG) stock fell 21.37% to $2.65. The market value of their outstanding shares is at $116.1 million.
    • Nexalin Technology (NASDAQ:NXL) stock declined by 15.45% to $0.38. The market value of their outstanding shares is at $2.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADAG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADAG
    $ALVO
    $AXDX
    $AZTR

    CompanyDatePrice TargetRatingAnalyst
    Alvotech
    $ALVO
    12/9/2025$5.00Underweight
    Barclays
    Adagene Inc.
    $ADAG
    11/24/2025$9.00Buy
    Guggenheim
    Alvotech
    $ALVO
    11/4/2025$8.00Buy → Hold
    Deutsche Bank
    Alvotech
    $ALVO
    10/14/2025$14.00Equal-Weight → Overweight
    Morgan Stanley
    Edgewise Therapeutics Inc.
    $EWTX
    9/25/2025$20.00Neutral
    Goldman
    Alvotech
    $ALVO
    9/23/2025$14.00Hold → Buy
    Deutsche Bank
    Adagene Inc.
    $ADAG
    8/6/2025$7.00Outperform
    Leerink Partners
    Edgewise Therapeutics Inc.
    $EWTX
    7/30/2025$46.00Strong Buy
    Raymond James
    More analyst ratings

    $ADAG
    $ALVO
    $AXDX
    $AZTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Altman Peter bought $5,650 worth of shares (5,000 units at $1.13), increasing direct ownership by 2% to 273,866 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    2/4/26 5:47:41 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Altman Peter bought $1,194 worth of shares (900 units at $1.33), increasing direct ownership by 0.34% to 268,866 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    1/21/26 5:03:15 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Altman Peter bought $1,444 worth of shares (1,100 units at $1.31), increasing direct ownership by 0.41% to 267,966 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    12/17/25 6:32:43 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADAG
    $ALVO
    $AXDX
    $AZTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Column Group Iii Gp, Lp sold $2,380,189 worth of shares (4,170,266 units at $0.57) (SEC Form 4)

    4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

    2/26/26 4:23:09 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Column Group Iii Gp, Lp sold $504,787 worth of shares (829,734 units at $0.61) (SEC Form 4)

    4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

    2/24/26 4:13:06 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SVP, Finance Higa Tomohiro sold $2,231 worth of shares (3,469 units at $0.64), decreasing direct ownership by 3% to 119,752 units (SEC Form 4)

    4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

    2/17/26 7:15:32 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADAG
    $ALVO
    $AXDX
    $AZTR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for SELARSDI issued to ALVOTECH USA INC

    Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-2) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:

    10/21/24 10:44:05 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SELARSDI issued to ALVOTECH USA INC

    Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-1) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:

    10/21/24 2:59:28 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SELARSDI issued to ALVOTECH USA INC

    Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-3) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:

    10/21/24 2:59:28 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADAG
    $ALVO
    $AXDX
    $AZTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BullFrog to Host Webinar on New Precision AI Capability

    GAITHERSBURG, Md., March 11, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence ("AI") and machine learning to turn complex biomedical data into actionable insights, will host a webinar in partnership with Xtalks Life Sciences, "Turning AI Recommendations into Clear, Defensible Decisions", about BullFrog AI's new precision AI capability on Friday, March 27, 2026 at 11 a.m. ET. The new AI capability advances the Company's end-to-end intelligence workflow by adding a strategic decision support layer on top of existing platforms bfPREP™ and bfLEAP®. Unlike traditional portfolio tools t

    3/11/26 8:00:00 AM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up

    –The MESA data show stabilization of function in participants on sevasemten versus the predicted functional decline observed in Becker natural history studies –– Data reinforce prior clinical findings of sevasemten in Becker, a rare disease with no approved treatments ––The GRAND CANYON placebo-controlled pivotal cohort is on track to readout in 4Q 2026 –BOULDER, Colo., March 10, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today presented at the 2026 MDA Clinical and Scientific Conference, long-term data from its MESA open-label extension study of sevasemten in Becker muscular dystrophy (Becker), a devastating genetic di

    3/10/26 7:00:00 AM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301's Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy

    Tenaya's Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting Drivers of DMD Cardiomyopathy  New Data Confirm TN-301's Differentiated Mechanism and Opportunities to Positively Address Rare and Prevalent Cardiac, Metabolic and Muscular Conditions Tenaya Plans to Advance TN-301 Toward Phase 2 Clinical Development ORLANDO, Fla. and SOUTH SAN FRANCISCO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today

    3/9/26 8:30:00 AM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADAG
    $ALVO
    $AXDX
    $AZTR
    SEC Filings

    View All

    SEC Form 8-K filed by Shuttle Pharmaceuticals Holdings Inc.

    8-K - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)

    3/10/26 5:00:43 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Shuttle Pharmaceuticals Holdings Inc.

    424B3 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)

    3/9/26 8:00:18 AM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Azitra Inc

    DEFA14A - Azitra, Inc. (0001701478) (Filer)

    3/5/26 4:36:04 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    $ALVO
    $AXDX
    $AZTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Alvotech with a new price target

    Barclays initiated coverage of Alvotech with a rating of Underweight and set a new price target of $5.00

    12/9/25 8:42:22 AM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on Adagene with a new price target

    Guggenheim initiated coverage of Adagene with a rating of Buy and set a new price target of $9.00

    11/24/25 8:15:55 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alvotech downgraded by Deutsche Bank with a new price target

    Deutsche Bank downgraded Alvotech from Buy to Hold and set a new price target of $8.00

    11/4/25 7:41:39 AM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADAG
    $ALVO
    $AXDX
    $AZTR
    Financials

    Live finance-specific insights

    View All

    Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results

    REYKJAVIK, Iceland, March 04, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO) (the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it will release its fourth quarter and full year 2025 financial and operating results on Wednesday, March 18, 2026, after the U.S. markets close. The Company will also host a conference call with a live Q&A on Thursday, March 19, 2026 at 08:00 EST (12:00 GMT, 13:00 CET). To listen to the webcast, register here: Q4 and Full Year 2025 webcast registrationTo participate in the Q&A, register here: Q4 and Full Year 2025 conference call registration Slid

    3/4/26 3:00:00 AM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC

    TN-401 was Well Tolerated at 3E13 vg/kg dose  Robust Transduction and Demonstrated Increases in PKP2 Protein Levels in First Two Patients at Week 8 Clinically Meaningful Reductions in Arrhythmia Burden Observed in First Two Patients with More Than Six Months of Follow-Up Tenaya Management to Host a Webcast Conference Call Thursday, December 11 at 5:00 pm ET to Review Preliminary Results SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced interim data

    12/11/25 4:01:00 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results

    SUNNYVALE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the third quarter of 2025 and filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2025 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management's formal remarks, there will be a question-and-answer session. "This quarter's $6 million financing is actively supporting approvability discussions of CardiAMP

    11/12/25 4:40:15 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADAG
    $ALVO
    $AXDX
    $AZTR
    Leadership Updates

    Live Leadership Updates

    View All

    Alvotech announces planned CEO succession and leadership transition

     - Róbert Wessman to continue serving as Executive Chairman in full-time capacity - Lisa Graver appointed Chief Executive Officer REYKJAVIK, Iceland, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced key senior leadership changes following a planned succession process. Founder Róbert Wessman, who has served as Chairman since the company's inception in 2013 and Chief Executive Officer since 2023, will transition out of the CEO role at the end of the first quarter of 2026. He will continue to serve as Executive Chairman in a full-time capac

    1/6/26 7:15:00 AM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

    BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee.  Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation.

    12/22/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality

    SUNNYVALE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces the appointment of Farhan Shahab as Vice President of Quality. Mr. Shahab brings over 25 years of experience to BioCardia in similar executive roles. Mr. Shahab joins BioCardia from Welldoc (a digital health company focused on chronic disease management), where he served as Vice President of Quality and Regulatory. Prior to that, he served as Senior Director of Regulatory Affairs and Quality Assurance at Intuity Medical (a blood glucose monitoring device company), and as Dir

    11/24/25 8:15:00 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADAG
    $ALVO
    $AXDX
    $AZTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Accelerate Diagnostics Inc.

    SC 13D/A - Accelerate Diagnostics, Inc (0000727207) (Subject)

    12/5/24 5:13:13 PM ET
    $AXDX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Edgewise Therapeutics Inc.

    SC 13G/A - Edgewise Therapeutics, Inc. (0001710072) (Subject)

    11/14/24 6:22:11 PM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tenaya Therapeutics Inc.

    SC 13G/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)

    11/14/24 5:46:12 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care